Acorda Therapeutics Inc
OTC:ACORQ

Watchlist Manager
Acorda Therapeutics Inc Logo
Acorda Therapeutics Inc
OTC:ACORQ
Watchlist
Price: 0.01 USD Market Closed
Market Cap: 20k USD

Acorda Therapeutics Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Acorda Therapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Acorda Therapeutics Inc
OTC:ACORQ
Revenue
$115.7m
CAGR 3-Years
-9%
CAGR 5-Years
-22%
CAGR 10-Years
-10%
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Acorda Therapeutics Inc
Glance View

Market Cap
20k USD
Industry
Biotechnology

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Ardsley, New York and currently employs 118 full-time employees. The company went IPO on 2006-02-10. The firm is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The firm uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). INBRIJA is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. INBRIJA utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

ACORQ Intrinsic Value
Not Available

See Also

What is Acorda Therapeutics Inc's Revenue?
Revenue
115.7m USD

Based on the financial report for Mar 31, 2024, Acorda Therapeutics Inc's Revenue amounts to 115.7m USD.

What is Acorda Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
-10%

Over the last year, the Revenue growth was -2%. The average annual Revenue growth rates for Acorda Therapeutics Inc have been -9% over the past three years , -22% over the past five years , and -10% over the past ten years .

Back to Top